Annexon, Inc. presented promising findings regarding its investigational therapy tanruprubart at the 2025 Peripheral Nerve Society Annual Meeting. The oral presentation highlighted the benefits of ...

Amid the near-total Israeli blockade, those in Gaza are facing a new threat to their lives — paralytic diseases. According to Nasser Hospital’s head of pediatrics, Dr. Ahmed Al-Farra, “Before the war, ...

Guillain-Barré Syndrome (GBS) is a rare but serious autoimmune disorder in which the immune system mistakenly attacks the peripheral nerves. Much like an electrical wire is insulated, nerves in the ...

DEAR DR. ROACH: I am a 73-year-old female with atrial fibrillation (AFib) who recently had a pacemaker implant and has been doing well since. I also have a thyroid gland disorder, and I’m taking daily ...

Results showed patients treated with ANX005 30mg/kg achieved a statistically significant 2.4-fold improvement on the GBS disability score at week 8 compared with placebo. Treatment with ANX005 was ...

NEW YORK, Oct. 18 (UPI) --A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus. The ...

A sudden spurt in Guillain-Barre Syndrome (GBS) in India's Maharashtra has raised health concerns with 101 cases being reported from Pune, as of January 26. According to a report in ANI, out of the ...

Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. ANX005 has the potential to become the first FDA approved therapy for ...

BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with ...

Guillain-Barre syndrome following a virus can damage nerves. Intense physical therapy needed to rebuild connections.